Texas A&M College of Dentistry
Welcome,         Profile    Billing    Logout  
 53 Trials 
70 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Ying
NCT05071482: Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Terminated
4
39
RoW
Flumatinib, Imatinib
Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia
01/23
01/23
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT04851613: Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
256
US, RoW
Afuresertib, Fulvestrant, Afuresertib/placebo
Laekna Limited
Breast Cancer
10/26
12/26
NCT05003245: Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed
3
407
RoW
HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
Shanghai Henlius Biotech
Age Related Macular Degeneration
05/24
05/24
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
551
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
Type 2 Diabetes Mellitus
03/25
12/25
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Completed
3
256
RoW
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
Shanghai Junshi Bioscience Co., Ltd.
Metastatic Melanoma, Unresectable Melanoma
07/23
11/23
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active, not recruiting
3
488
RoW
TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis
TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
09/24
02/25
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
SYSKY-2023-1016-01, NCT06255392: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting
3
200
RoW
Fluzoparib, Apatinib Mesylate, Capecitabine tablets, Vinorelbine Tartrate Oral, Eribulin mesylate injection, Gemcitabine Hydrochloride, Paclitaxel-albumin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
03/31
03/31
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
12/26
12/26
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Recruiting
3
350
RoW
Olverembatinib, Imatinib
Ascentage Pharma Group Inc., HealthQuest Pharma Inc.
Ph+ ALL
12/24
10/28
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Not yet recruiting
3
408
RoW
TQF3510 (Semaglutide Injection), Wegovy®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
07/26
08/26
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
3
532
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
03/25
03/27
NCT07043725: A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Not yet recruiting
3
544
RoW
TQB2102 for injection, Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
09/27
09/29
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Recruiting
3
474
RoW
Intensity Modulated Radiation Therapy, IMRT, Chemotherapy
Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital
Nasopharyngeal Carcinoma, Radiotherapy; Complications
05/25
05/28
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Recruiting
3
288
RoW
Disitamab vedotin, RC48, Endocrine therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HR Positive/HER2 Low Expression Metastatic Breast Cancer
03/28
03/30
NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Recruiting
3
516
RoW
Fulvestrant combined with Pyrotinib, FASLODEX combined with Pyrotinib, Capecitabine combined with Pyrotinib, xeloda combined with Pyrotinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
12/28
12/30
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Not yet recruiting
2b
2250
RoW
TNM001, placebo
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
05/26
08/26
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Recruiting
2
46
RoW
Pyrotinib combined with fulvestrant
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Breast Cancer
07/21
07/22
NCT06429098: Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Recruiting
2
40
RoW
Venetoclax, ABT-199, ABT199, Venclexta, azacitidine, 5 AZC, 5-AZC, decitabine, Dacogen, Cytarabine, 1-.beta.-Cytosine arabinoside, Ara-C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
06/27
12/27
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Recruiting
2
50
RoW
Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
Chongqing University Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
03/24
08/24
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting
2
60
RoW
HLX07+HLX10+ Cisplatin+5-FU, HLX07
Shanghai Henlius Biotech
ESCC or Esophageal Adenosquamous Carcinoma
06/24
08/25
Camresbrt, NCT04830267: The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Recruiting
2
39
RoW
Camrelizumab, Anti-PD-1 antibody, Stereotactic body radiotherapy, SBRT
Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma
08/24
08/26
RD13-02, NCT05454241: CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Completed
2
14
RoW
Anti-CD7 CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Hematological Malignancies
08/24
08/24
IIT2022040-EC-1, NCT05594784: Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Completed
2
79
RoW
Olverembatinib, Venetoclax, prednisone, Vincristine
Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
03/25
03/25
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043

Recruiting
2
202
RoW
ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
Abbisko Therapeutics Co, Ltd
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
11/29
06/30
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12/27
12/27
NCT05213884: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Recruiting
2
30
RoW
Camrelizumab, Anti-PD-1 antibody, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT)
Chongqing University Cancer Hospital
Head and Neck Squamous Cell Carcinoma
01/25
01/27
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Recruiting
2
45
RoW
Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Chongqing University Cancer Hospital, Fujian Cancer Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma
10/27
10/27
CALLIOPSIS, NCT06776757: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Recruiting
1/2
30
RoW
Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Metastatic Colorectal Cancer
06/25
12/25
CN201-103, NCT05579132: A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Recruiting
1/2
203
RoW
MK-1045, CN201
MSD R&D (China) Co., Ltd.
Acute Lymphoblastic Leukemia
01/27
01/27
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
NCT07153068: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Recruiting
1/2
12
RoW
supCD7 CART cells
Institute of Hematology & Blood Diseases Hospital, China
T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
06/28
06/30
NCT07059221: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Not yet recruiting
1/2
96
RoW
SHR-A2102, Adebrelimab, Cetuximab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
03/26
03/28
NCT07107204: A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Not yet recruiting
1/2
116
NA
BT02
Biotroy Therapeutics
Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
01/28
04/28
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Recruiting
1
316
RoW
HSK42360
Haisco Pharmaceutical Group Co., Ltd.
Solid Tumors
08/26
07/27
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

Not yet recruiting
1
33
RoW
HDM1002
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Adult Subject
11/24
12/24
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/26
12/26
NCT07038720: A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis

Recruiting
1
124
RoW
UA026, Placebo
Usynova Pharmaceuticals Ltd.
Plaque Psoriasis, Healthy Volunteer
03/26
06/26
NCT06880354: A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
37
RoW
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Institute of Hematology & Blood Diseases Hospital, China, Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca
Acute Myeloid Leukemia
03/28
03/28
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/27
11/29
NCT07169487: Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Recruiting
1
18
RoW
Methylene Blue
Institute of Hematology & Blood Diseases Hospital, China
Cytokine Release Syndrome, ICANS
06/28
06/30
NCT07123519: A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Not yet recruiting
1
18
RoW
YTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antiphospholipid Syndrome (APS)
08/26
08/27
NCT06725706: Beta Amyloid PET/CT in Various Aβ-Related Disease

Recruiting
N/A
500
RoW
18F-92/AV45, 11C-PIB
Tianjin Medical University, Tianjin Medical University General Hospital
Amyloid, Beta-Amyloid, Neurodegenerative Diseases
12/27
12/27
TJMUGH-05, NCT06690983: Tau PET/CT in Various Tau-Related Disease Patients

Recruiting
N/A
500
RoW
18F-S16/T807
Tianjin Medical University, Tianjin Medical University General Hospital
Tauopathies, Neurodegenerative Diseases, Neurodegeneration
11/27
12/27
NCT06725719: Translocator Protein PET/CT in Various TSPO-Related Disease

Recruiting
N/A
200
RoW
18F-DPA714/FDPA
Tianjin Medical University, Tianjin Medical University General Hospital
Neuroinflammation, Stroke, Neurodegenerative Diseases
12/27
12/27
NCT05360043: Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores

Recruiting
N/A
27
RoW
laser treatment
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enlarged Facial Pores
04/22
10/22
NCT04800575: Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter

Recruiting
N/A
154
RoW
semi-permeable film, sterile gauze and tape
Peking University People's Hospital
Infection, Bacterial
05/22
12/22
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Available
N/A
RoW
CAR-T cells
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
Relapsed and Refractory Hematological Malignancies
 
 
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life

Completed
N/A
2000
RoW
Peking University People's Hospital
Post Surgical Pain
05/23
05/23
CONSTICHILD, NCT03941925: Prebiotic Fructans Effect on 1-3 Years Constipated Children's Bowel Habits

Recruiting
N/A
100
RoW
Prebiotic fructans, Non-prebiotic maltodextrin
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH
Constipation
12/22
12/22
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein

Completed
N/A
120
RoW
Commercially Available Starter Infant Formula
Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems
Digestion, Gut Microbiota
12/22
12/22
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
URG-APD, NCT03754361: The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis

Terminated
N/A
34
RoW
automated peritoneal dialysis, IHD
Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital
ESRD
07/22
12/22
NCT05540795: Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT

Completed
N/A
15
RoW
Fifth Affiliated Hospital, Sun Yat-Sen University
Parathyroid Gland Disease, Secondary Hyperparathyroidism
05/23
07/23
NCT06167109: NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma

Recruiting
N/A
60
RoW
CTV optimized IMRT
Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V8 Stage
05/26
10/26
NCT05014893: Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline

Recruiting
N/A
100
RoW
multi-modal targeted intervention (e.g., cognitive training, exercise, games)
National Research Center for Rehabilitation Technical Aids, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province, Central South University, Beijing academy of science and technology, Beijing University of Chinese Medicine
Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy
12/26
12/26
NCT06511453: Acupressure in Patients With Sickle Cell Disease

Recruiting
N/A
240
US
Acupressure (using AcuWand or pencil eraser)
Indiana University, University of California, Irvine
Sickle Cell Disease
02/29
08/29
NCT05992285: A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum

Completed
N/A
68
RoW
transcranial magnetic stimulation
Xijing Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.1 Hospital, Xi'an International Medical Center Hospital, Xi'an Hospital of Traditional Chinese Medicine
Insomnia Disorder
10/24
10/24
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation

Recruiting
N/A
40
US
Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental
Hailey Bivens
Recession, Gingival
09/24
03/25
NCT05483790: The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment

Completed
N/A
120
RoW
the multimodal intervention
Huashan Hospital, School of Public Health，Fudan University, Medicine-Mental Health Center of Minhang District, Xinzhuang Community Health Service Center
Mild Cognitive Impairment, The Cognitive Normal Elderly
12/24
12/24
NCT06725550: Integrative Medicine in Pain Management in Sickle Cell Disease

Not yet recruiting
N/A
120
US
needling acupuncture, laser acupuncture
Indiana University
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
02/29
02/30
NCT06949670: Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Recruiting
N/A
500
RoW
18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
Tianjin Medical University, Tianjin Medical University General Hospital
Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
04/28
04/28
NCT05045820: Integrative Medicine in Pain Management in Sickle Cell Disease

Recruiting
N/A
60
US
needling acupuncture, laser acupuncture
Indiana University, National Center for Complementary and Integrative Health (NCCIH)
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
05/25
05/26
NCT04683757: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Recruiting
N/A
288
RoW
Establishment of a Survival Prediction Model
Ying Wang
Breast Cancer
01/21
12/24
NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Recruiting
N/A
80
RoW
Eribulin, Halaven, Trastuzumab, Herceptin, pertuzumab, Perjeta, Pyrotinib, Pembrolizumab, Keytruda, Camerlizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
12/22
12/23
COAS-CAS, NCT05629000: Optimization Strategy of Carotid Artery Stenosis

Recruiting
N/A
1000
RoW
Carotid revascularization, carotid endarterectomy and carotid artery stent, MRI-PWI, CTA, PET/MRI, Ultrasound
Peking Union Medical College Hospital
Carotid Artery Stenosis
12/25
12/26
Bivens, Hailey
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation

Recruiting
N/A
40
US
Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental
Hailey Bivens
Recession, Gingival
09/24
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Ying
NCT05071482: Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Terminated
4
39
RoW
Flumatinib, Imatinib
Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia
01/23
01/23
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT04851613: Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
256
US, RoW
Afuresertib, Fulvestrant, Afuresertib/placebo
Laekna Limited
Breast Cancer
10/26
12/26
NCT05003245: Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed
3
407
RoW
HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
Shanghai Henlius Biotech
Age Related Macular Degeneration
05/24
05/24
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
551
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
Type 2 Diabetes Mellitus
03/25
12/25
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Completed
3
256
RoW
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
Shanghai Junshi Bioscience Co., Ltd.
Metastatic Melanoma, Unresectable Melanoma
07/23
11/23
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active, not recruiting
3
488
RoW
TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis
TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
09/24
02/25
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
SYSKY-2023-1016-01, NCT06255392: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting
3
200
RoW
Fluzoparib, Apatinib Mesylate, Capecitabine tablets, Vinorelbine Tartrate Oral, Eribulin mesylate injection, Gemcitabine Hydrochloride, Paclitaxel-albumin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
03/31
03/31
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
12/26
12/26
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Recruiting
3
350
RoW
Olverembatinib, Imatinib
Ascentage Pharma Group Inc., HealthQuest Pharma Inc.
Ph+ ALL
12/24
10/28
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Not yet recruiting
3
408
RoW
TQF3510 (Semaglutide Injection), Wegovy®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
07/26
08/26
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
3
532
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
03/25
03/27
NCT07043725: A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Not yet recruiting
3
544
RoW
TQB2102 for injection, Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
09/27
09/29
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Recruiting
3
474
RoW
Intensity Modulated Radiation Therapy, IMRT, Chemotherapy
Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital
Nasopharyngeal Carcinoma, Radiotherapy; Complications
05/25
05/28
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Recruiting
3
288
RoW
Disitamab vedotin, RC48, Endocrine therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HR Positive/HER2 Low Expression Metastatic Breast Cancer
03/28
03/30
NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Recruiting
3
516
RoW
Fulvestrant combined with Pyrotinib, FASLODEX combined with Pyrotinib, Capecitabine combined with Pyrotinib, xeloda combined with Pyrotinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
12/28
12/30
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Not yet recruiting
2b
2250
RoW
TNM001, placebo
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
05/26
08/26
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Recruiting
2
46
RoW
Pyrotinib combined with fulvestrant
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Breast Cancer
07/21
07/22
NCT06429098: Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Recruiting
2
40
RoW
Venetoclax, ABT-199, ABT199, Venclexta, azacitidine, 5 AZC, 5-AZC, decitabine, Dacogen, Cytarabine, 1-.beta.-Cytosine arabinoside, Ara-C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
06/27
12/27
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Recruiting
2
50
RoW
Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
Chongqing University Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
03/24
08/24
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting
2
60
RoW
HLX07+HLX10+ Cisplatin+5-FU, HLX07
Shanghai Henlius Biotech
ESCC or Esophageal Adenosquamous Carcinoma
06/24
08/25
Camresbrt, NCT04830267: The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Recruiting
2
39
RoW
Camrelizumab, Anti-PD-1 antibody, Stereotactic body radiotherapy, SBRT
Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma
08/24
08/26
RD13-02, NCT05454241: CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Completed
2
14
RoW
Anti-CD7 CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Hematological Malignancies
08/24
08/24
IIT2022040-EC-1, NCT05594784: Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Completed
2
79
RoW
Olverembatinib, Venetoclax, prednisone, Vincristine
Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
03/25
03/25
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043

Recruiting
2
202
RoW
ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
Abbisko Therapeutics Co, Ltd
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
11/29
06/30
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12/27
12/27
NCT05213884: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Recruiting
2
30
RoW
Camrelizumab, Anti-PD-1 antibody, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT)
Chongqing University Cancer Hospital
Head and Neck Squamous Cell Carcinoma
01/25
01/27
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Recruiting
2
45
RoW
Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Chongqing University Cancer Hospital, Fujian Cancer Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma
10/27
10/27
CALLIOPSIS, NCT06776757: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Recruiting
1/2
30
RoW
Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Metastatic Colorectal Cancer
06/25
12/25
CN201-103, NCT05579132: A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Recruiting
1/2
203
RoW
MK-1045, CN201
MSD R&D (China) Co., Ltd.
Acute Lymphoblastic Leukemia
01/27
01/27
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
NCT07153068: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Recruiting
1/2
12
RoW
supCD7 CART cells
Institute of Hematology & Blood Diseases Hospital, China
T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
06/28
06/30
NCT07059221: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Not yet recruiting
1/2
96
RoW
SHR-A2102, Adebrelimab, Cetuximab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
03/26
03/28
NCT07107204: A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Not yet recruiting
1/2
116
NA
BT02
Biotroy Therapeutics
Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
01/28
04/28
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Recruiting
1
316
RoW
HSK42360
Haisco Pharmaceutical Group Co., Ltd.
Solid Tumors
08/26
07/27
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

Not yet recruiting
1
33
RoW
HDM1002
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Adult Subject
11/24
12/24
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/26
12/26
NCT07038720: A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis

Recruiting
1
124
RoW
UA026, Placebo
Usynova Pharmaceuticals Ltd.
Plaque Psoriasis, Healthy Volunteer
03/26
06/26
NCT06880354: A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
37
RoW
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Institute of Hematology & Blood Diseases Hospital, China, Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca
Acute Myeloid Leukemia
03/28
03/28
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/27
11/29
NCT07169487: Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Recruiting
1
18
RoW
Methylene Blue
Institute of Hematology & Blood Diseases Hospital, China
Cytokine Release Syndrome, ICANS
06/28
06/30
NCT07123519: A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Not yet recruiting
1
18
RoW
YTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antiphospholipid Syndrome (APS)
08/26
08/27
NCT06725706: Beta Amyloid PET/CT in Various Aβ-Related Disease

Recruiting
N/A
500
RoW
18F-92/AV45, 11C-PIB
Tianjin Medical University, Tianjin Medical University General Hospital
Amyloid, Beta-Amyloid, Neurodegenerative Diseases
12/27
12/27
TJMUGH-05, NCT06690983: Tau PET/CT in Various Tau-Related Disease Patients

Recruiting
N/A
500
RoW
18F-S16/T807
Tianjin Medical University, Tianjin Medical University General Hospital
Tauopathies, Neurodegenerative Diseases, Neurodegeneration
11/27
12/27
NCT06725719: Translocator Protein PET/CT in Various TSPO-Related Disease

Recruiting
N/A
200
RoW
18F-DPA714/FDPA
Tianjin Medical University, Tianjin Medical University General Hospital
Neuroinflammation, Stroke, Neurodegenerative Diseases
12/27
12/27
NCT05360043: Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores

Recruiting
N/A
27
RoW
laser treatment
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enlarged Facial Pores
04/22
10/22
NCT04800575: Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter

Recruiting
N/A
154
RoW
semi-permeable film, sterile gauze and tape
Peking University People's Hospital
Infection, Bacterial
05/22
12/22
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Available
N/A
RoW
CAR-T cells
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
Relapsed and Refractory Hematological Malignancies
 
 
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life

Completed
N/A
2000
RoW
Peking University People's Hospital
Post Surgical Pain
05/23
05/23
CONSTICHILD, NCT03941925: Prebiotic Fructans Effect on 1-3 Years Constipated Children's Bowel Habits

Recruiting
N/A
100
RoW
Prebiotic fructans, Non-prebiotic maltodextrin
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH
Constipation
12/22
12/22
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein

Completed
N/A
120
RoW
Commercially Available Starter Infant Formula
Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems
Digestion, Gut Microbiota
12/22
12/22
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
URG-APD, NCT03754361: The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis

Terminated
N/A
34
RoW
automated peritoneal dialysis, IHD
Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital
ESRD
07/22
12/22
NCT05540795: Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT

Completed
N/A
15
RoW
Fifth Affiliated Hospital, Sun Yat-Sen University
Parathyroid Gland Disease, Secondary Hyperparathyroidism
05/23
07/23
NCT06167109: NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma

Recruiting
N/A
60
RoW
CTV optimized IMRT
Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V8 Stage
05/26
10/26
NCT05014893: Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline

Recruiting
N/A
100
RoW
multi-modal targeted intervention (e.g., cognitive training, exercise, games)
National Research Center for Rehabilitation Technical Aids, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province, Central South University, Beijing academy of science and technology, Beijing University of Chinese Medicine
Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy
12/26
12/26
NCT06511453: Acupressure in Patients With Sickle Cell Disease

Recruiting
N/A
240
US
Acupressure (using AcuWand or pencil eraser)
Indiana University, University of California, Irvine
Sickle Cell Disease
02/29
08/29
NCT05992285: A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum

Completed
N/A
68
RoW
transcranial magnetic stimulation
Xijing Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.1 Hospital, Xi'an International Medical Center Hospital, Xi'an Hospital of Traditional Chinese Medicine
Insomnia Disorder
10/24
10/24
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation

Recruiting
N/A
40
US
Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental
Hailey Bivens
Recession, Gingival
09/24
03/25
NCT05483790: The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment

Completed
N/A
120
RoW
the multimodal intervention
Huashan Hospital, School of Public Health，Fudan University, Medicine-Mental Health Center of Minhang District, Xinzhuang Community Health Service Center
Mild Cognitive Impairment, The Cognitive Normal Elderly
12/24
12/24
NCT06725550: Integrative Medicine in Pain Management in Sickle Cell Disease

Not yet recruiting
N/A
120
US
needling acupuncture, laser acupuncture
Indiana University
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
02/29
02/30
NCT06949670: Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Recruiting
N/A
500
RoW
18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
Tianjin Medical University, Tianjin Medical University General Hospital
Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
04/28
04/28
NCT05045820: Integrative Medicine in Pain Management in Sickle Cell Disease

Recruiting
N/A
60
US
needling acupuncture, laser acupuncture
Indiana University, National Center for Complementary and Integrative Health (NCCIH)
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
05/25
05/26
NCT04683757: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Recruiting
N/A
288
RoW
Establishment of a Survival Prediction Model
Ying Wang
Breast Cancer
01/21
12/24
NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Recruiting
N/A
80
RoW
Eribulin, Halaven, Trastuzumab, Herceptin, pertuzumab, Perjeta, Pyrotinib, Pembrolizumab, Keytruda, Camerlizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
12/22
12/23
COAS-CAS, NCT05629000: Optimization Strategy of Carotid Artery Stenosis

Recruiting
N/A
1000
RoW
Carotid revascularization, carotid endarterectomy and carotid artery stent, MRI-PWI, CTA, PET/MRI, Ultrasound
Peking Union Medical College Hospital
Carotid Artery Stenosis
12/25
12/26
Bivens, Hailey
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation

Recruiting
N/A
40
US
Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental
Hailey Bivens
Recession, Gingival
09/24
03/25

Download Options